The phase I trial NCT03260504 is evaluating aldesleukin plus pembrolizumab for metastatic ccRCC, based on the premise that aldesleukin can potentiate anti-cancer immune responses which pembrolizumab may enhance by blocking immune evasion [76]. This evidence concerns the gene IL2 and cancer.